Comparison of response and toxicity of capecitabine and oxaliplatin chemotherapy regimen with taxol and carboplatin with radiotherapy in esophageal cancer patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170306032913N4

Enrollment

Registered

2020-02-16

Start date

2017-03-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemoradiotherapy in esophageal cancer patients. Malignant neoplasm of esophagus

Interventions

Intervention 1: Control group of 35 esophageal cancer patients receiving weekly paclitaxel (75mg/m2) and carboplatin (AUC:2)regimen with 5 days a week radiotherapy ( total dose:45-50Gy). Interventi

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Proper Performance Status. No severe dysphagia

Exclusion criteria

Exclusion criteria: Age over 80. Cervical Esophageal involvement

Design outcomes

Primary

Measure	Time frame
Pathologic and clinical response to chemoradiotherapy with two different regimens in esophageal cancer patients. Timepoint: Evaluation of response rate after completion of chemoradiotherapy and evaluation and comparison of complications during treatment. Method of measurement: Postoperative pathology report. EUS re-report after chemoradiotherapy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Nikoofar

Iran University of Medical Sciences

arnikoofar@gmail.com+98 21 8214 1792

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026